Your email has been successfully added to our mailing list.

×
0 0 3.57142857142025E-05 3.57142857142025E-05 0.0321071428571429 0.0232142857142857 0.0178571428571428 0.00967857142857139
Stock impact report

Edesa Biotech in-licenses two COVID-19 candidates; shares up 21% [Seeking Alpha]

Edesa Biotech, Inc. - Common Shares (EDSA) 
Company Research Source: Seeking Alpha
Thinly traded nano cap Edesa Biotech (EDSA+21.1%agreementThe monoclonal antibodies inhibit the signaling proteins TLR4 and CXCL10, respectively.Under the terms of the deal, Edesa will issue $2.5M of Series A-1 Convertible Preferred Stock to Light Chain subject to meeting certain milestones, near-term consideration of $6.0M for inventory and other milestone fees, up to $363.5M in development, regulatory and sales milestones and royalties on net sales. Show less Read more
Impact Snapshot
Event Time:
EDSA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for EDSA alerts
Opt-in for
EDSA alerts

from News Quantified
Opt-in for
EDSA alerts

from News Quantified